Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration

HAMBURG, Germany, Sept. 2, 2008 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(Nasdaq:EVTC) today announced that a third milestone has been successfully
achieved in their collaboration with Boehringer Ingelheim. Under the terms of
the drug discovery contract, Evotec will receive a milestone payment from
Boehringer Ingelheim which was granted for the selection of an advanced compound
for profiling to enable the start of preclinical development.

Further projects within the multi-target collaboration are progressing and are
on track to achieve additional project milestones for which Evotec is entitled
to receive additional payments from Boehringer Ingelheim. Furthermore, the
contract provides substantial long-term upside through potential payments for
successful milestone achievements during clinical development and royalties when
new drugs reach the market. Further financial details of the payment were not
disclosed.

Dr John Kemp, Chief Research and Development Officer at Evotec, commented: "We
are proud to have achieved this important milestone in one of our projects with
Boehringer Ingelheim. This further demonstrates our capabilities to discover
novel drugs based on our drug discovery expertise. Our collaboration with
Boehringer Ingelheim is progressing very well and we are looking forward to
continued success."

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule
drugs. Both through its own discovery programs and through research
collaborations, it is generating the highest quality research results to its
partners in the pharmaceutical and biotechnology industries. In proprietary
projects, Evotec specializes in finding new treatments for diseases of the
Central Nervous System. Evotec has three programs in clinical development: EVT
201, a partial positive allosteric modulator (pPAM) of the GABAA receptor
complex for the treatment of insomnia, EVT 101, a subtype selective NMDA
receptor antagonist for the treatment of Alzheimer's disease and/or pain, and
EVT 302, a MAO-B inhibitor in development for smoking cessation. Evotec's
proprietary preclinical research programs focus on the purinergic receptors,
P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In
addition, Evotec has worldwide collaboration and license agreements with Pfizer
to research, develop and commercialize small molecule vanilloid receptor (VR1)
antagonists. For additional information please go to www.evotec.com

Forward-Looking Statements

Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. Such forward-looking
statements include, but are not limited to, statements about our expectations
and assumptions concerning regulatory, clinical and business strategies, the
progress of our clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans, objectives and
strategies. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured; risks
relating to our ability to advance the development of product candidates
currently in the pipeline or in clinical trials; our inability to further
identify, develop and achieve commercial success for new products and
technologies; competing products may be more successful; our inability to
interest potential partners in our technologies and products; our inability to
achieve commercial success for our products and technologies; our inability to
protect our intellectual property and the cost of enforcing or defending our
intellectual property rights; our failure to comply with regulations relating to
our products and product candidates, including FDA requirements; the risk that
the FDA may interpret the results of our studies differently than we have; the
risk that clinical trials may not result in marketable products; the risk that
we may be unable to successfully secure regulatory approval of and market our
drug candidates; and risks of new, changing and competitive technologies and
regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our Annual Report on Form 20-F, filed
with the Securities and Exchange Commission, and other documents filed with, or
furnished to the Securities and Exchange Commission, contain additional factors
that could impact our businesses and financial performance. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations or
any change in events, conditions or circumstances on which any such statement is
based.

-0-
CONTACT: Evotec AG
Anne Hennecke, SVP, Investor Relations &
Corporate Communications
+49.(0)40.56081-286
Fax: +49.(0)40.56081-333
anne.hennecke@evotec.com